P344: THE DUAL BCL-2 AND BCL-XL INHIBITOR AZD4320 SHOWS ON-TARGET ACTIVITY IN ALL AND ACTS SYNERGISTICALLY WITH MCL-1 INHIBITION
Main Authors: | M. C. Wichert, A. Niedermayer, S. Enzenmüller, K.-M. Debatin, L. H. Meyer, F. Seyfried |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000844264.32857.90 |
Similar Items
Similar Items
-
BCL-XL regulates the timing of mitotic apoptosis independently of BCL2 and MCL1 compensation
by: Chun Yin Yu, et al.
Published: (2024-01-01) -
Synergistic Action of MCL-1 Inhibitor with BCL-2/BCL-XL or MAPK Pathway Inhibitors Enhances Acute Myeloid Leukemia Cell Apoptosis and Differentiation
by: Małgorzata Opydo, et al.
Published: (2023-04-01) -
Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice
by: Sajid Khan, et al.
Published: (2023-01-01) -
Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
by: Mike-Andrew Westhoff, et al.
Published: (2022-01-01) -
Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
by: Enyuan Shang, et al.
Published: (2020-08-01)